REGENXBIO Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021; filed March 1, 2022. This is an annual report, not a standalone fourth-quarter filing. REGENXBIO is a clinical-stage gene-therapy company whose revenue comes from licensing its NAV AAV-vector platform and royalties; it had no sales of its own products.
Business context and development
The company’s internal pipeline targets retinal, neuromuscular and neurodegenerative diseases. Key candidates include RGX-314 (retinal disease, partnered with AbbVie), RGX-202 (Duchenne muscular dystrophy), RGX-121 and RGX-111 (MPS II and MPS I), and RGX-181 and RGX-381 (CLN2 disease). Its platform is also used by licensees, including for Novartis’s marketed Zolgensma.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $470.3 million | $154.6 million |
| Operating expenses | $310.4 million | $273.8 million |
| Operating income (loss) | $160.0 million | $(119.2) million |
| Net income (loss) | $127.8 million | $(111.3) million |
| Operating cash flow | $218.9 million | $(54.1) million |
| Cash, cash equivalents and marketable securities at year-end | $849.3 million | $522.5 million |
- Revenue rose approximately 204%. The main driver was a $370.0 million upfront payment under the AbbVie RGX-314 agreement; Zolgensma royalties also increased to $95.0 million from $61.6 million.
- Derived from reported figures, FY2021 gross margin was approximately 89% (revenue less cost of revenues) and operating margin approximately 34%. These figures reflect the substantial upfront collaboration revenue and should not be read as recurring product economics.
- R&D expense increased 9% to $181.4 million; general and administrative expense increased 24% to $79.3 million. Operating cash flow benefited substantially from AbbVie’s upfront payment and higher Zolgensma royalties.
- Current assets were $518.8 million and current liabilities $130.5 million at year-end, a derived current ratio of approximately 4.0x. Management stated available cash and investments were expected to fund operations and capital needs for at least 12 months from the report date.
- The balance sheet included a $171.3 million liability related to the sale of future Zolgensma royalties to HCR ($37.9 million current; $133.5 million non-current) and $86.7 million of operating lease liabilities. The filing describes the HCR arrangement as a capped royalty sale accounted for as a liability; it is not presented as conventional borrowings.
Material changes and unusual items
- AbbVie’s collaboration became effective in November 2021. REGENXBIO received $370.0 million upfront and may receive up to $1.38 billion in development and sales milestones. U.S. commercialization profits and losses are to be shared equally; AbbVie leads commercialization outside the U.S., with REGENXBIO eligible for tiered royalties.
- Zolgensma royalties were $95.0 million, but REGENXBIO sold a portion of that royalty stream to HCR in 2020. The company paid HCR $48.2 million in royalties during 2021 and recognized $26.3 million of related imputed interest expense.
- REGENXBIO raised $216.1 million net through a January 2021 common-stock offering, issuing 4.899 million shares. Shares outstanding increased from 37.5 million at year-end 2020 to 42.8 million at year-end 2021.
- Operating cash flow turned positive, but the result was driven by collaboration and royalty receipts; the company expects regular operating cash outflows as development continues. Investing cash flow was negative $406.6 million, including $84.2 million of property and equipment purchases, primarily for its Rockville headquarters and manufacturing buildout.
- The company reported an immaterial correction to 2021 interim cash-flow classifications: imputed-interest portions of HCR royalty payments should have been operating rather than financing cash outflows. The annual statements reflect the corrected classification; prior interim balance sheets and results were unaffected.
Outlook, risks and contingencies
- Management expected the subretinal RGX-314 pivotal trials, ATMOSPHERE and ASCENT, to support a BLA submission in 2024. This is a stated development expectation, not a guarantee. The company’s broader goal was to have multiple AAV therapies approved or in pivotal trials by the end of 2025.
- RGX-202’s first-in-human Phase I/II trial was expected to begin in the first half of 2022. The company also described positive interim findings announced after year-end for RGX-314, RGX-121 and RGX-111; these were preliminary clinical observations, not proof of efficacy or regulatory approval.
- Key risks include clinical safety and efficacy uncertainty, trial enrollment and timing, regulatory and manufacturing hurdles, competition, reliance on third-party manufacturers and collaborators, and concentrated, contingent license and royalty revenue. AbbVie and Novartis accounted for approximately 99% of FY2021 revenue.
- COVID-19 had caused trial and facility-construction delays and could cause further disruption. The company said FY2021 results were not significantly affected, while noting future effects remained uncertain.
- Abeona settled a dispute over a terminated license for $30.0 million: $20.0 million was paid in November 2021, with $5.0 million due in November 2022 and another $5.0 million due by November 2024 or upon a specified transaction. REGENXBIO recorded a $3.8 million allowance against the non-current receivable.
- The filing reports patent-infringement actions against Sarepta and Aldevron, with uncertain outcomes, and describes Penn/GSK questions about sublicense fees and the applicable Zolgensma royalty category. The potential financial exposure from these disputes is not clearly quantified in the filing text.
Most important facts for investors to verify
- Whether RGX-314 pivotal trials remain on schedule and what subsequent data, safety findings, and manufacturing-bridging results show.
- How much of future revenue is recurring Zolgensma royalties versus collaboration upfronts, milestones and other contingent license payments; verify AbbVie’s cost-sharing and milestone conditions.
- Current cash and investment balances, operating cash burn excluding large upfront receipts, and projected spending to complete the manufacturing facility and advance trials.
- Developments in the Abeona settlement collections and the Penn/GSK royalty and sublicense-fee questions, including any resulting payments or changes to royalty economics.
- Whether customer concentration, clinical and manufacturing risks, and any new safety or regulatory developments materially change the company’s outlook.